 xxxd1983xxx  benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.  simultaneous agonism of the mu-opioid receptor and antagonism of the delta-opioid receptor can reduce abdominal pain and diarrhea in patients with irritable bowel syndrome with diarrhea (ibs-d) without constipating side effects. we evaluated the efficacy and safety of a minimally absorbed, mu-opioid receptor agonist and delta-opioid receptor antagonist ( xxxd1983xxx ) in a phase 2 study in patients with ibs-d.clinical trial; dor; drug; eq-5d; euroqol-5 dimension; fda; functional bowel disorders; glmm; ibs; ibs-d; ibs-qol; ibs-quality of life; ibs-sss; ibs-symptom severity score; ivrs; mor; transit; us food and drug administration; wap; generalized linear mixed effects model; interactive voice response system; irritable bowel syndrome; irritable bowel syndrome with diarrhea; worst abdominal pain;  xxxg1632xxx ;  xxxg1635xxx 